Latest News
Bluejay Diagnostics, Inc.
- Bluejay Diagnostics (Nasdaq:BJDX) - Stock Analysis
- Bluejay completes Toray milestone: what the deadline means for Bluejay Diagnostics stock
- Acton’s Bluejay Diagnostics reaches manufacturing milestone for sepsis test
- Bluejay Diagnostics completes manufacturing site milestone
- Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
- A cartridge site for a sepsis test is set up ahead of Bluejay's Oct. 23 deadline.
- Bluejay Diagnostics reports SYMON-II dataset: 777 patients, ~18% 28-day mortality for IL-6 evaluation
- Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
- What's Moving Biotech Stocks Pre-Market? Bluejay Diagnostics (NASDAQ:BJDX), Kairos Pharma (NYSE:KAPA), Rezolute (NASDAQ:RZLT) in Focus
- Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
- Bluejay Diagnostics, Inc. Announces SYMON-II Clinical Dataset Details Supporting Evaluation Of Mortality Risk In Sepsis And Septic Shock
- Among 777 patients with sepsis or septic shock, 140 did not survive 28 days in Bluejay's study.
Headlines from the last 30 days, linking to the original publishers. See all market news →